Zenith Capital nombró al abogado de Calgary Bryan Ede en su junta directiva, reemplazando al director retirado Dr. Norman Wong. Zenith Capital appointed Calgary lawyer Bryan Ede to its board, replacing retiring director Dr. Norman Wong.

Zenith Capital Corp. nombró a Bryan R. Ede, J.D., en su Junta de Directores el 3 de marzo de 2026, sucediendo al director retirado Dr. Norman Wong, M.D. Zenith Capital Corp. appointed Bryan R. Ede, J.D., to its Board of Directors on March 3, 2026, succeeding retiring director Dr. Norman Wong, M.D. Ede, un abogado comercial con sede en Calgary con más de 27 años de experiencia, anteriormente se desempeñó como socio de capital en McMillan LLP y Miller Thomson LLP, desempeñando funciones de liderazgo, incluido el socio gerente de Calgary y presidente de grupos de práctica legal. Ede, a Calgary-based commercial lawyer with over 27 years of experience, previously served as an equity partner at McMillan LLP and Miller Thomson LLP, holding leadership roles including Calgary Managing Partner and Chair of legal practice groups. Su experiencia abarca atención médica, bienes raíces, comercio minorista y petróleo y gas, con un enfoque en asuntos comerciales transaccionales y estratégicos. His expertise spans healthcare, real estate, retail, and oil and gas, with a focus on transactional and strategic business matters. La empresa, cuya filial Zenith Epigenetics Ltd. está desarrollando fármacos para el tratamiento del cáncer, incluido ZEN-3694 en ensayos clínicos, señaló que sus declaraciones prospectivas están sujetas a riesgos e incertidumbres. The company, whose subsidiary Zenith Epigenetics Ltd. is developing cancer therapeutics, including ZEN-3694 in clinical trials, noted that its forward-looking statements are subject to risks and uncertainties.